With the support of Enterprise Europe Network, Op2lysis has been selected by EU-Japan to be part of the Biotech Cluster SME mission.
This selection will provide Op2lysis with the opportunity to attend BioJapan Expo 2019, next October. This mission will allow the company to meet with Japanese companies.
This mission comes at the right time for Op2lysis, as it will allow us to extend a network of contacts and to favour a partnership with a Japanese company in order to integrate Japan at the early stage of our clinical development.
Hemorrhagic stroke accounts for about 30% of all strokes in Japanese patients. Japan is the world’s second-largest market for hemorrhagic stroke.
With the support of the Enterprise Europe Network France, we are very proud of having been selected among many candidates for this mission. With this great opportunity, we hope to produce the best possible benefit for our development.
For more information : Click here